10 MAY

Rapid Start-up and Tight FPI Timeline for US Biotech Clinical Trial

 

Overview

After a sudden decision to expedite their study timelines, a US Biotech company approached PharmaSols in need of a CRO who could successfully achieve a quality rapid start-up within a tight timeline.

PharmaSols’ expertise in navigating through local ethics and regulatory submission requirements and attaining approval gave our sponsor the confidence that this was a challenge we could handle.

Accelerated by our efficiency, precision, and willingness to go the extra mile, our rapid start-up team was able to review and identify changes in the final protocol, obtain the necessary approvals, and meet the sponsor’s FPI timeline despite it falling on a Sunday.

Challenges

This study came with a few challenges:

  • Change in study submission date (from contract sign to ethics submission shortened to less than a week)
  • Only a draft protocol was initially available
  • The draft Protocol required a full review, amendments made, and sponsor sign off
  • The final target FPI date fell on a Sunday

The Outcome

Despite the short submission timelines, the rapid start-up team ensured that all documents were developed, quality controlled and submitted within the sponsor’s timeframe.

Our team assisted in the review and suggested amendments to the draft protocol. Along with our extensive knowledge of local ethics committee requirements, we were also able to prepare the ethics submission rapidly.

The study received full ethics and regulatory approval on time. While there were some minor queries from the ethics committee, the collaborative effort between PharmaSols, the principal investigator, and the sponsor meant these were resolved quickly and smoothly, all still within the tight timeline.

At PharmaSols, we maintain strong, reliable relationships with our sites. The site understood the importance of the sponsor’s FPI target and they allowed administration of the first patient dose on a Sunday.

The sponsor initially recognised PharmaSols’ ability to achieve a rapid start-up, but in the end, it was also our people-driven attitude and flexible problem solving that led to the success of this trial.

Case Studies

Expedited Timelines and Recruitment Success for COVID-19 Vaccine Trial

While the pandemic has slowed down most of the globe, it has increased the demand for rapid solutions within the pharmaceutical industry, with an urgent need to find a vaccine and COVID-19 related treatments and vaccines. Running clinical trials for potential solutions is a vital element in this process.

Read more
Exceeding Site Identification Targets Across Three Recent Clinical Trial Studies

Site identification is the first and most critical deliverable from a CRO. Without an appropriate site, there is no patient recruitment, and without patients, there is no study.

Read more
High Recruitment: Twice as many patients as global CRO

Faced with a challenging recruitment process, needing to recruit a large number of elderly participants within a tight three-month seasonal recruitment window, a US-based Biotech Company appointed PharmaSols as the NZ CRO for this phase three respiratory clinical trial.

Read more
Rapid start-up: First SIV in less than 35 days

Having previously worked with PharmaSols over a number of trials, the US sponsor knew that the PharmaSols team could deliver on both tight start-up timelines and high recruitment targets. PharmaSols proven record of flexible, rapid, and creative solutions meant we were the ideal CRO partner.

Read more
Creative Solutions for US Biotech Clinical Trial

A US-based Biotech company was seeking a CRO who could successfully recruit a large number of elderly research participants in New Zealand. A challenge that was not only squeezed into a three-month seasonal recruitment window but was also met with issues so unique, there were no established protocols.

Read more
Quick Feasibility for Rare Genetic Trial

A US Biotech company reached out to PharmaSols, to investigate the feasibility of running a trial in New Zealand on participants' stored tissue samples, where consent had been given for further research to identify a rare genetic marker.

Read more